Trial reportPatient preference and adherence2025
Antirheumatic Medication Calendar Significantly Improves Adherence in First-Time Methotrexate Users: A Prospective, Single-Blind, Randomized Controlled Trial.
Trial report in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The relationship between medication possession index and functional prognosis in patients with rheumatoid arthritis: a national longitudinal cohort study from CHARLS.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Methotrexate is widely used to treat rheumatoid arthritis; however, the adherence rate greatly varies due to its weekly dosing schedule. Incorrect administration can lead to disease progression and toxicity. To design a graphic-based medication calendar aiming to improve adherence in first-time methotrexate users. Patients and Methods: This prospective, single-blind, randomized controlled trial included participants aged 18-75 years who were starting methotrexate for the first time or resuming it after a 3-month break. Seventy-nine participants from October 1, 2023, to January 30, 2024, were randomly assigned in a 1:1 ratio to the calendar (38 participants) or control (41 participants) group for 6 weeks and followed up for 2, 6, and 10 weeks. The primary outcome was methotrexate adherence, assessed by the proportion of patients with a PDC value of 100%. Results: After 6 and 10 weeks, the calendar group had a higher proportion of patients with a PDC value of 100% compared with the control group (97.2% vs 73.2%, P < 0.004; 88.9% vs 68.9%, P < 0.03, respectively) and a higher correct medication adherence rate within 10 weeks (87.81% vs 69%, P = 0.0307). Compared with the control group, the calendar group had a significantly higher rate of on-time return visits during both follow-up visits (97.2% vs 78.0% and 91.7% vs 70.7%, respectively). Additionally, 94.74% of the calendar group patients believed the intervention improved their adherence and wished to continue using it. Conclusion: The antirheumatic medication calendar improved initial methotrexate adherence; however, its effect diminished following its discontinuation. Clinical Trial Registration: ChiCTR2300076228 (2023-09-27).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.